Related Experiment Video
Updated: May 21, 2026

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
Published on: April 7, 2023
Structural characterization of a fructan from Polygonati Rhizoma and its anti-diabetic effects associated with
Chang Xue1,2,3, Zijun Li1,2, Lulu Yao2
1National Key Laboratory of Macromolecular Drugs and Large-scale Preparation, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Abstract:
Type 2 diabetes mellitus (T2DM) involves insulin resistance, hyperglycaemia, and metabolic stress. Polygonati Rhizoma (Huangjing), a traditional edible and medicinal plant widely used in East Asia, has gained attention as a functional food resource. In this study, a fructan-rich polysaccharide fraction (PRP-W-1) was purified and characterized by HPGPC, FT-IR, GC-MS, and NMR. PRP-W-1 showed a single HPGPC peak with a weight-average molecular weight of approximately 4.8 kDa and consisted mainly of fructose ( > 93%) with minor glucose. Linkage and NMR analyses indicated that PRP-W-1 is a low-molecular-weight fructan mainly composed of a 1,2-linked fructofuranosyl backbone, together with a minor glucosyl component and limited branching. In HFD/STZ-induced T2DM mice, PRP-W-1 mitigated body-weight loss, lowered fasting glucose, improved glucose tolerance, and enhanced insulin sensitivity. It also attenuated dyslipidaemia and liver index elevations. PRP-W-1 was associated with increased hepatic PI3K and p-AKT, reduced p-JNK, and restored adipose GLUT4 abundance. It also improved intestinal barrier-related markers, reshaped the gut microbiota, and increased cecal short-chain fatty acids (SCFAs). Collectively, these results identify PRP-W-1 as a structurally defined, low-molecular-weight fructan from Polygonati Rhizoma with hypoglycaemic and gut-modulatory effects, supporting its potential as a natural dietary ingredient for metabolic health.
Related Concept Videos
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are typically...
Dipeptidyl Peptidase 4 Inhibitors
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Oral Hypoglycemic Agents: Biguanides and Glitazones
Insulin: The Receptor and Signaling Pathways
Overview of Carbohydrate Metabolism
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
